Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension

Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension

Sponsors

Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Collaborator: Jiangsu Carefree Pharmaceutical Co., Ltd.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Guangdong Provincial People's Hospital
Sir Run Run Shaw Hospital
The First Affiliated Hospital of Zhengzhou University
Dongguan People's Hospital
Second Affiliated Hospital of Xi'an Jiaotong University
Beijing Chao Yang Hospital
Beijing Anzhen Hospital
The Affiliated Hospital of Qingdao University

Source The First Affiliated Hospital of Guangzhou Medical University
Brief Summary

Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the main pharmacologically active natural compound from a traditional Chinese herbal medicine,the dried root of Salvia miltiorrhiza Bunge known as Danshen. Danshen has been known for the function of improving body functions such as activating blood circulation and removing blood stasis according to the theory of traditional Chinese medicine. Danshen and its various formula products including STS have been long-time widely used in oriental countries, especially China to treat various inflammatory and cardiovascular diseases for its pharmacological actions, including vasodilatation, anticoagulation, anti-inflammation, and free radical scavenging,with negligible adverse effects observed.

The investigator's objective is to evaluate whether STS exhibits beneficial effects on pulmonary hypertension. This is a randomized, controlled, multicentre clinical trial study. 90 patients with pulmonary hypertension will be enrolled in this study.

Overall Status Unknown status
Start Date May 2013
Completion Date December 2014
Primary Completion Date December 2014
Phase Phase 2/Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
mPAP by right heart catheterization At the end of 0- and 8-week trial
Secondary Outcome
Measure Time Frame
WHO functional class of pulmonary hypertension(PH) At the end of 0-,2-, 4-,6- and 8-week of trial
Borg dyspnea score At the end of 0-, 2-,4-,6- and 8-week trial
Minnesota living with heart failure questionnaire At the end of 0-,2-, 4-,6- and 8-week trial
6-minute walk distance (6MWD) At the end of 0-, 2-, 4-, 6- and 8-week trial
Pulmonary vascular resistance(PVR) measured by right heart catheterization At the end of 0- and 8-week trial
Enrollment 90
Condition
Intervention

Intervention Type: Drug

Intervention Name: 20 mg sildenafil citrate by mouth

Description: 20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks

Arm Group Label: 20 mg sildenafil citrate tablets by mouth

Other Name: Viagra

Intervention Type: Drug

Intervention Name: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth

Description: sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment

Arm Group Label: sodium tanshinone IIA sulfonate, sildenafil citrate tablets

Eligibility

Criteria:

Inclusion Criteria:

1. Meet the condition of mean pulmonary arterial pressure (mPAP) ≥25 mmHg at seal level at rest and pulmonary capillary wedge pressure(PCWP)≤15mmHg;

2. Category 1 or 4 of PH in stable stage according to 2008 Dana Point Conference,including the idiopathic, hereditary, drugs and toxins induced, associated with connective tissue disease or congenital heart disease, and chronic thromboembolic pulmonary arterial hypertension(PAH) ;

3. Male or female between 15 to 70 years old;

4. WHO pulmonary hypertension functional class II or III;

5. The baseline 6-minute walk distance between 150-550 m;

6. Patients' condition should be stable for more than one month after basic treatment; For those patients with congenital heart disease, surgery should have been performed six months or more before they are enrolled in the study;

7. Patients receiving sildenafil treatment only previously, or those without target drugs treatment during the past 3 months;

8. Patients or their guardians should agree with this clinical trail and medical informed consent of the trial should be signed.

Exclusion Criteria:

1. Unavailable or limited legal capacity;

2. Pregnant or lactational women;

3. Important organs with severe diseases;

4. Mental or physical disability;

5. With suspected or indeed alcohol, drug abuse history;

6. With allergic constitution, with two or more drugs or foods allergy history or those who are allergic to any components of the experimental drugs;

7. With both aspartate aminotransferase (AST) and glutamic-pyruvic transaminase (ALT) more than three times of the upper limit of normal in liver function test and Ccr≤50ml/min in kidney function test;

8. Those with systemic blood pressure<90/50 mmHg, or those uncontrolled dangerous hypertension(BP>170/110 mmHg);

9. Patients at active stages of infectious or other diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis, and some connective tissue diseases;

10. Patients with severe infection, especially pulmonary infection;

11. Patients with shock or astable hemodynamics with other causes;

12. Patients with hepatic cirrhosis, and hepatic cirrhosis induced portal hypertension;

13. Patients with severe hemorrhage, and hemorrhagic tendency;

14. Patients who need to take or be taking drugs possible or indeed affecting this trial;

15. Patients cannot accomplish required items (especially 6MWD) because of acute/chronic organic disease (excluding dyspnea) or other illnesses such as lower extremity diseases;

16. Patients with any other conditions considered cannot be recruited.

Gender: All

Minimum Age: 15 Years

Maximum Age: 70 Years

Healthy Volunteers: No

Overall Contact

Last Name: Jian Wang, MD

Phone: +8615013388183

Email: [email protected]

Location
Facility: Status: Contact: The First Affiliated Hospital of Guangzhou Medical University Jian Wang, MD +8615013388183 [email protected]
Location Countries

China

Verification Date

March 2014

Responsible Party

Type: Principal Investigator

Investigator Affiliation: The First Affiliated Hospital of Guangzhou Medical University

Investigator Full Name: Nanshan Zhong

Investigator Title: Professor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: 20 mg sildenafil citrate tablets by mouth

Type: Active Comparator

Description: 20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks

Label: sodium tanshinone IIA sulfonate, sildenafil citrate tablets

Type: Experimental

Description: sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration

Acronym STS
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov